Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Certificates

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 12 result(s)
COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the National MS Society, Consortium of MS Centers and Multiple Sclerosis Society of Canada to capture information on outcomes of people with MS and other CNS demyelinating diseases (Neuromyelitis Optica, or MOG antibody disease) who have developed COVID-19.
Country
We developed a method, ChIP-sequencing (ChIP-seq), combining chromatin immunoprecipitation (ChIP) and massively parallel sequencing to identify mammalian DNA sequences bound by transcription factors in vivo. We used ChIP-seq to map STAT1 targets in interferon-gamma (IFN-gamma)-stimulated and unstimulated human HeLa S3 cells, and compared the method's performance to ChIP-PCR and to ChIP-chip for four chromosomes.For both Chromatin- immunoprecipation Transcription Factors and Histone modifications. Sequence files and the associated probability files are also provided.
Country
BenchSci is a free platform designed to help biomedical research scientists quickly and easily identify validated antibodies from publications. Using various filters including techniques, tissue, cell lines, and more, scientists can find out published data along with the antibody that match specific experimental contexts within seconds. Free registration & access for academic research scientists.
Country
Since 2004, the Leibniz Institute for Prevention Research and Epidemiology – BIPS has been working on the establishment and maintenance of the project-based German Pharmacoepidemiological Research Database (short GePaRD). GePaRD is based on claims data from statutory health insurance (SHI) providers and currently includes information on about 20 million persons who have been insured with one of the participating providers since 2004. Per data year, there is information on approximately 17% of the general population from all geographical regions of Germany.
The Cancer Immunome Database (TCIA) provides results of comprehensive immunogenomic analyses of next generation sequencing data (NGS) data for 20 solid cancers from The Cancer Genome Atlas (TCGA) and other datasource. The Cancer Immunome Atlas (TCIA) was developed and is maintained at the Division of Bioinformatics (ICBI). The database can be queried for the gene expression of specific immune-related gene sets, cellular composition of immune infiltrates (characterized using gene set enrichment analyses and deconvolution), neoantigens and cancer-germline antigens, HLA types, and tumor heterogeneity (estimated from cancer cell fractions). Moreover it provides survival analyses for different types immunological parameters. TCIA will be constantly updated with new data and results.
Country
The Biobanque québécoise de la COVID-19 (BQC19) is a pan-provincial initiative that collects, stores and shares data and blood samples from COVID-19 patients, both severe and non-severe cases and control cases, in an effort to respond effectively to the public health challenges posed by the pandemic. BQC19 believes that better understanding the disease will help society in returning to social activities and in preparing for future pandemics. It sees access to high-quality samples and data as essential in fulfilling research and works to bring about national and international research collaborations.
Country
From April 2020 to March 2023, the Covid-19 Immunity Task Force (CITF) supported 120 studies to generate knowledge about immunity to SARS-CoV-2. The subjects addressed by these studies include the extent of SARS-CoV-2 infection in Canada, the nature of immunity, vaccine effectiveness and safety, and the need for booster shots among different communities and priority populations in Canada. The CITF Databank was developed to further enhance the impact of CITF funded studies by allowing additional research using the data collected from CITF-supported studies. The CITF Databank centralizes and harmonizes individual-level data from CITF-funded studies that have met all ethical requirements to deposit data in the CITF Databank and have completed a data sharing agreement. The CITF Databank is an internationally unique resource for sharing epidemiological and laboratory data from studies about SARS-CoV-2 immunity in different populations. The types of research that are possible with data from the CITF Databank include observational epidemiological studies, mathematical modelling research, and comparative evaluation of surveillance and laboratory methods.
The Immunology Database and Analysis Portal (ImmPort) archives clinical study and trial data generated by NIAID/DAIT-funded investigators. Data types housed in ImmPort include subject assessments i.e., medical history, concomitant medications and adverse events as well as mechanistic assay data such as flow cytometry, ELISA, ELISPOT, etc. --- You won't need an ImmPort account to search for compelling studies, peruse study demographics, interventions and mechanistic assays. But why stop there? What you really want to do is download the study, look at each experiment in detail including individual ELISA results and flow cytometry files. Perhaps you want to take those flow cytometry files for a test drive using FLOCK in the ImmPort flow cytometry module. To download all that interesting data you will need to register for ImmPort access.
IMGT/mAb-DB provides a unique expertised resource on monoclonal antibodies (mAbs) with diagnostic or therapeutic indications, fusion proteins for immune applications (FPIA), composite proteins for clinical applications (CPCA) and relative proteins of the immune system (RPI) with clinical indications.
Content type(s)
The Antibody Registry supports the RRID Initiative and exists to give researchers a way to universally identify antibodies used in publications. The registry lists many commercial antibodies from over 200 vendors, which have been assigned a unique identifier and over 2000 individual laboratories. If the antibody that you are using does not appear in the list, an entry can be made by filling in as little as 2 pieces of information: the catalog number and the url of the vendor where our curators can find information and material data sheets.